Interim report 1 April – 30 June, 2016
Second quarter compared to 2015, Group
» Group net sales increased by 78% to SEK 469,380 (263,909).
» Other operating income amounted to SEK 381,298 (1,110,025).
» Income after financial items amounted to SEK –16,473,988 (–11,384,072).
First six months 2015, compared to first six months 2015, Group
» Group net sales increased by 80% to SEK 881,214 (490 920).
» Other operating income amounted to SEK 946,584 (2,566,400). » Income after financial items amounted to SEK –28,170,735 (–18,917,297).
» Earnings per share (weighted average) amounted to SEK –1.00 (–1.43).
» Equity per share amounted to SEK –5.16 (2.58).
» Equity ratio amounted to 94.1% (79.1).
Significant events during the second quarter
» Clinical results based on 1 and 2 year follow up data were presented for the first time with excellent results where the patients show significant improvements regarding pain and mobility.
» The 100th surgery was performed in the beginning of June 2016.
» The current sales force expansion project was completed by the hiring of two additional sales representatives in Germany and two in the UK.
» A “pre-submission dossier” was submitted to the FDA.
» Episurf Medical attend its first large European knee meeting, ESSKA (European Society of Sports Traumatology, Knee Surgery and Arthroscopy).
» Further reimbursement was received from a number of private health care providers in the UK, the Netherlands and in Belgium.
Significant events after the second quarter
» Episurf Medical’s nomination committee proposed Mr. Dennis Stripe and Mr. Wil Boren as new board members of Episurf Medical, to be elected at an extra general meeting on August 18 2016. Mr. Dennis Stripe and Mr. Wil Boren both have extensive experience from the orthopaedic industry.
» Episurf Medical obtained a new granted patent in Europe covering a surgical drilling guide which was the first patent in this family of patents to be granted.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
rosemary@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 10 August 2016.